471 related articles for article (PubMed ID: 26016953)
1. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
3. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M
Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary arterial hypertension in connective tissue diseases.
Goldberg A
Cardiol Rev; 2010; 18(2):85-8. PubMed ID: 20160534
[TBL] [Abstract][Full Text] [Related]
5. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
6. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
[TBL] [Abstract][Full Text] [Related]
8. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center.
Shirai Y; Yasuoka H; Takeuchi T; Satoh T; Kuwana M
Mod Rheumatol; 2013 Nov; 23(6):1211-20. PubMed ID: 23359006
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Petrovič M; Locatelli I
Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
[No Abstract] [Full Text] [Related]
11. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
[TBL] [Abstract][Full Text] [Related]
12. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
Langleben D; Orfanos SE; Giovinazzo M; Hirsch A; Baron M; Senécal JL; Armaganidis A; Catravas JD
Arthritis Rheum; 2008 Apr; 58(4):1156-64. PubMed ID: 18383374
[TBL] [Abstract][Full Text] [Related]
14. [Pulmonary arterial hypertension associated with connective tissue diseases].
Legendre P; Mouthon L
Presse Med; 2014 Sep; 43(9):957-69. PubMed ID: 25129118
[TBL] [Abstract][Full Text] [Related]
15. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
[TBL] [Abstract][Full Text] [Related]
16. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease.
Nakanishi N; ;
Allergol Int; 2011 Dec; 60(4):419-24. PubMed ID: 22015568
[TBL] [Abstract][Full Text] [Related]
17. Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
Ascha M; Zhou X; Rao Y; Minai OA; Tonelli AR
Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28643420
[TBL] [Abstract][Full Text] [Related]
18. Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study.
Hay BR; Pugh ME; Robbins IM; Hemnes AR
Chest; 2016 Mar; 149(3):660-6. PubMed ID: 26378379
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
[TBL] [Abstract][Full Text] [Related]
20. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Pan J; Lei L; Zhao C
Clin Exp Rheumatol; 2018; 36(6):1095-1102. PubMed ID: 29998831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
